|
|
| (40 intermediate revisions not shown) |
| Line 1: |
Line 1: |
| - | == '''Brainstorming''' ==
| |
| - | <html>
| |
| - | <h2>Bacterial sunscreen</h2>
| |
| | | | |
| - | - Evidence suggests that several components found in most sunscreens are harmful to us and can be carcinogenic, also most sunscreens only protect against UV B (315-280 nm) and not UV A
| |
| - | <br>
| |
| - | - These sunscreens use metal oxides (Zinc oxide) to absorb UV radiation, but the effects of absorbing these metals into your skin are not fully understood and are thought to lead to production of reactive oxygen species and could lead to melanomas rather than preventing them.
| |
| - | <br>
| |
| - | - Scytonemin is a pigment found in cyanobacteria which protects them from UV radiation, absorbing 325-425nm. Its synthesis requires three enzymes, SycA-C
| |
| - | <br>
| |
| - | Mycosporine-like amino acids (MAAs) are produced by organisms adapted to environments with high levels of sunlight (eg. cyanobacteria and algae), protecting them from UV radiation. There are 20 types and they also serve as anti-oxidants by stabilising free radicals (anti-ageing?). In a bioinformatics study the genes YP_324358 (predicted DHQ synthase) and YP_324357 (O-methyltransferase) were identified in A. variabilis PCC 7937 cyanobacteria. (http://www.sciencedirect.com/science/article/pii/S0888754309002353)
| |
| - | MAAs have already been recognised to have sunscreen potential and are found in some anti-wrinkle creams <BR>
| |
| - | - gene cluster encoding 4 enzymes required for all MAA synthesis. Expressed this gene cluster from a cyanobacterium into E. coli and got pigment production. (Text by Nikki)
| |
| - | <BR>
| |
| - |
| |
| - | <h2>Prodigiosin pigment</h2>
| |
| - | - UV protecting properties <BR>
| |
| - | - synthesis controlled by quorum sensing<BR>
| |
| - | - absorbs in UV range from 240 to 400 nm as well as in the visible spectrum from 400 to 600 nm<BR>
| |
| - | - also antibiotic and anti-cancer (induces NAG-1 pro-apoptotic gene in human breast cancer cells)<BR>
| |
| - | - Prodigiosin biosynthesis gene cluster (pig cluster) contains ~15 ORFs in <EM>Serratia</EM> strains (Harris <EM>et al.,</EM> 2004)<br>
| |
| - | - PigS and PigP regulate prodigiosin biosynthesis in <EM>Serratia </EM>(Gristwood <EM>et al.,</EM> 2011)<br>
| |
| - | - Streptomyces griseoviridis 2464-S5 produces prodigiosin R1, gene cluster of 24 open reading frames, including 21 genes (rphD-rphZ) homologous to prodigiosin biosynthesis genes in the red cluster in Streptomyces coelicolor A3(2). The expression of rphN in S. coelicolor lacking redN restored the production of prodigiosin (Kawasaki <EM>et al.,</EM> 2009)<br>
| |
| - | - could also be used as a dye in clothing. pigment production from microorganisms by large-scale fermentation would be environmentally friendly and sustainable. Could make clothes with inherent UV protection, but they would all be red....
| |
| - | (Text by Nikki)
| |
| - | <br>
| |
| - |
| |
| - | <h2>Synthetic graphite</h2>
| |
| - | - Synthetic Graphite normally has a high electrical conductivity than the natural ones.
| |
| - | <br>
| |
| - | - the process involves turning amorphous carbon into crystal under extremely high temperature.
| |
| - | <br>
| |
| - | <p>- no evidence shows that carbon(element) can be either iuput or output of bacterial metabolism.
| |
| - | <br>
| |
| - | - therefore, we can pass this topic (Text by Nina)<br>
| |
| - |
| |
| - |
| |
| - | <h2>Anti-venom</h2>
| |
| - | - traditional way of anti-venom production:<br>
| |
| - | 1. injecting venom or detoxified venom into a horse (tiny amount, multiple times)<br>
| |
| - | 2. after the antigen growing period, contract the horse blood plasma<br>
| |
| - | 3. use stomach digestive enzyme to breakdown the anti-venom protein into smaller globin<br>
| |
| - | 4. use (NH4)2SO4 to salt out the globin (purification) [1]<br>
| |
| - | <br>
| |
| - | - oxides like K<sub>2</sub>MnO<sub>4</sub> can neutralise venom by denaturing the polypeptide chains
| |
| - | <br>
| |
| - | - complex ligase like AuCl<sub>2</sub> can denature venom by binding with them, when preventing venom entering the tissues [2]
| |
| - | <br>
| |
| - | -immune system has a stronger response to venom [3]. When the mast cells are stimulated, they release histamine. Histamine can subside the venom
| |
| - | <br>
| |
| - | - histamine producing bacteria: found in tuna; 18 types of bacteria such as Clostridium perfringens and other anaerobic bacteria
| |
| - | <br><br>
| |
| - | - to conclude:<br>
| |
| - | 1. decide the working mechanism (toxicology) of a specific type of venom: does it attack neurons? brain cells? cardiovascular system? respiratory system?<br>
| |
| - | 2. does it react with histamine?<br>
| |
| - | 3. bacterial production of histamine<br>
| |
| - | <br>
| |
| - | REFERENCES:
| |
| - | [1]<a href="http://en.wikipedia.org/wiki/Antivenom">http://en.wikipedia.org/wiki/Antivenom</a><br>
| |
| - | [2] <a href="http://life.91sqs.com/html/zazhi/yixueyushehui/2011/0113/1453.html">http://life.91sqs.com/html/zazhi/yixueyushehui/2011/0113/1453.html</a><br>
| |
| - | [3] “ Development of antibody against Naja naja atra venom using phage display and single-chain Fv antibody technology ” Master Graduation Paper NUK
| |
| - | <a href="http://ethesys.nuk.edu.tw/ETD-db/ETD-search-c/view_etd?URN=etd-0825110-170246">http://ethesys.nuk.edu.tw/ETD-db/ETD-search-c/view_etd?URN=etd-0825110-170246</a> (Text by Nina)
| |
| - | <br>
| |
| - |
| |
| - | <h2>Alkaloid isorhy against Parkinson's</h2>
| |
| - | - It is rumoured to be a potential treatment for Parkinson's and it would make a good project if this were to be produced by bacteria<br>
| |
| - | - On further research it turns out that the evidence for this drug as a treatment is weak and there is no information available about the gene or genes that encode it, so the idea was dropped (Text by Frank)
| |
| - | <br>
| |
| - | <h2>Bacterial tattoo</h2>
| |
| - | - After being inspired by a student from the Royal College of Arts who presented us with her work on a project to create a living dress, Frank began to research the notion of a melanin tattoo, so that alpha-melanin stimulating hormone is applied to the skin and held in place until the skin darkens in the shape of the template. The alpha-MSH could be produced by bacteria.<br>
| |
| - | - the alpha-MSH gene is produced as one gene that also contains beta-MSH and gamma-MSH that are made available through post-transcriptional processing, so only the alpha-MSH region is required as it is the best characterised and has been expressed before<br>
| |
| - | - Once the alpha-MSH is expressed, it can be collected, soaked into silk (for example) that is cut into a pattern and will allow the hormone to diffuse into the skin, producing a (probably temporary) tattoo. From: <a href="http://en.wikipedia.org/wiki/Melanocyte-stimulating_hormone"> http://en.wikipedia.org/wiki/Melanocyte-stimulating_hormone </a><br>
| |
| - | - However, it seems that alpha-MSH is a rather powerful aphrodisiac and so a different hormone will have to be chosen, in addition, it seems that the hormone is unlikely to penetrate the skin as there are many different layers as well as proteases secreted by the skin<br>
| |
| - | - alpha-MSH, or its analogues are already used as tanning solutions and the analogues are considerably stronger<br>
| |
| - | - so then, bacteria could express the gene for melanotan - which is a cyclic lactyam analogue, and this will be very difficult to express, as a method will have to be found for cyclisation.<br>
| |
| - | - One further problem:
| |
| - |
| |
| - | "As of 2010 no compound incorporating the melanotan II peptide has ever been approved for use by any governmental drug regulatory bodies outside of clinical trials. Unlicensed and untested powders sold as "melanotan II" are found on the Internet and are reported to be used by thousands of members of the general public. Multiple regulatory bodies have warned consumers the peptides may be unsafe and ineffective in usage with one regulatory agency warning that consumers who purchase any product labeled "melanotan" risk buying a counterfeit drug. Medical researchers and Clinuvel Pharmaceuticals, the company developing the related peptide afamelanotide, has warned consumers that counterfeit products sold using the names "melanotan I and II", "pose a hazard to public health"." From <a href="http://en.wikipedia.org/wiki/Melanotan">http://en.wikipedia.org/wiki/Melanotan</a><br>
| |
| - |
| |
| - | - alpha-MSH will have to be used, but this time with the novel method for crossing the skin: Transdermal iontophoresis. This is a non-invasive way for hydrophilic proteins to be transported across the skin but I do not know what kind of resolution is possible with this device. Whatever the pattern achieved, be it a nice dot or a blotted smudge, the students from the RCA will surely help to make it look pretty.
| |
| - | (Text by Frank)<br>
| |
| - |
| |
| - | <h2>Vampiric bacteria</h2>
| |
| - | -The aspect of a Vampiric bacteria that is designed to get rid of blood clots produced by trauma induced clotting or during complex medical procedures is intriguing. <br>
| |
| - | -Expression of Hirudin is possible in systems such as E. coli. In 2007 Berkeley produced a chassis for a E. coli that could
| |
| - | be introduced into the blood stream after inactivation. <br>
| |
| - | -However, it is difficult to have the non-viable cell lysis occur in the correct location and therefore an anticoagulant could just as well be injected into the patient. <br>
| |
| - | -For this to work, we would require an expression system that is able to express Hirudin (produced usually by leech salivary glands and has been successfully expressed in E. coli [1]), express anti-angiotensin (it is possible to express Fab fragments in E. coli [2]) and targeting the fibrin (can be done by expressing Tissue plasminogen activator). <br>
| |
| - | -The idea would be to have the chassis recognize a blood clot or an area of damage and prevent clotting and/or clear clots. A method for having the system recognize when to secrete hirudin would be by having the bacteria sense trauma related chemokines and have the chassis secrete the protein only when it senses above a certain threshold of these chemokines or we could try to express protease-activated receptors (GPCR) that are cleaved by activated thrombin (the target of hirudin). Direct application would only benefit over the use of leeches in that the chassis is more aseptic then a leech bite.
| |
| - | The biggest issue remains the fact that for this to work we would have to inject the patient with living E. coli that can evade the human immune system.<br><br>
| |
| - | A new method of boosting biosynthesis has been obtained through the use of RNA scaffolds:
| |
| - | http://www.sciencemag.org/content/early/2011/06/22/science.1206938<br>
| |
| - | <br>
| |
| - | Reference:<br>
| |
| - | <a href="http://www.ncbi.nlm.nih.gov/pubmed/12182823">[1]</a>Shuhua Tan et al., “Efficient expression and secretion of recombinant hirudin III in E. coli using the L-asparaginase II signal sequence,” Protein Expression and Purification 25, no. 3 (August 2002): 430-436.
| |
| - | <br>
| |
| - | <a href="http://www.ncbi.nlm.nih.gov/pubmed/17045651">[2]</a>Saad A Masri et al., “Cloning and expression in E. coli of a functional Fab fragment obtained from single human lymphocyte against anthrax toxin,” Molecular Immunology 44, no. 8 (March 2007): 2101-2106.<br>
| |
| - | <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90939/">[3]</a>Ji Qiu, James R. Swartz, and George Georgiou, “Expression of Active Human Tissue-Type Plasminogen Activator in Escherichia coli,” Applied and Environmental Microbiology 64, no. 12 (December 1998): 4891-4896. (Text by Chris)
| |
| - |
| |
| - | <h2>Converting fallen leaves into useful products</h2>
| |
| - | -Aquatic hyphomycetes has been recognized as critical for controlling the process of leaf litter breakdown. The activity of this fungus is affected by C:N ratio, lignin content, pH of water, temperature, and abundance of nutrients
| |
| - | (i.e. O<sub>2</sub>). They produce B-glucosidase, Cellobiohyhrolase (cbhI family), B-xylosidase (xlnR) and phenoloxidase (Pox2) to promote leaf degradation. <br>
| |
| - | -As leaves decay, they produce heat. Leaves will decompose into an excellent organic soil amendment
| |
| - | that can be used as a soil conditioner.<br>
| |
| - | -The decomposition process is slow (i.e. leaves require 5 months to 2 years to decompose), could combine with Nick’s gene
| |
| - | expression amplification? <br>
| |
| - | -However, rapid decomposition would consume a large amount of O<sub>2 </sub>and create anaerobic conditions. Could we engineer all these into facultative anaerobes?<br><br>
| |
| - |
| |
| - | References:
| |
| - |
| |
| - | [1] FEMSMicrobiolLett 264(2006)246–254, DOI:10.1111/j.1574-6968.2006.00462.x<br>
| |
| - |
| |
| - | [2] E.N. Tamayo et al. / Fungal Genetics and Biology 45 (2008) 984–993, doi:10.1016/j.fgb.2008.03.002<br>
| |
| - |
| |
| - | [3] APPLIED AND ENVIRONMENTAL MICROBIOLOGY, June 2008, p. 3481–3489, doi:10.1128/AEM.02893-07<br>
| |
| - |
| |
| - | [4] Mutagenesis Advance Access published June 15, 2006, doi:10.1093/mutage/gel025<br>
| |
| - |
| |
| - | [5] <a href="http://herbarium.usu.edu/fungi/funfacts/decay.htm">http://herbarium.usu.edu/fungi/funfacts/decay.htm</a><br>
| |
| - |
| |
| - | [6] <a href="http://onlinelibrary.wiley.com/doi/10.1002/iroh.201111355/pdf">http://onlinelibrary.wiley.com/doi/10.1002/iroh.201111355/pdf</a> (Text by Yuanwei)<br>
| |
| - |
| |
| - |
| |
| - |
| |
| - | <h2>Fuel from food waste</h2>
| |
| - |
| |
| - | -Microbes in food waste like heterotrophs, cyanobacteria, microalgae and purple bacteria produce <b>biohydrogen</b>. Hydrogen has more potential energy than petrol. Hence, food waste can be turned into valuable energy. <b>Fermentative bacteria</b> use carbohydrates like sugar to produce hydrogen and acids. <b>Purple bacteria</b>, use light to produce energy (photosynthesis) and make hydrogen to help them break down molecules such as acids.
| |
| - | <a href="http://www.sciencedaily.com/releases/2008/07/080716204805.htm">http://www.sciencedaily.com/releases/2008/07/080716204805.htm</a><br>
| |
| - |
| |
| - | -Hydrogen is produced by feeding waste products from a chocolate factory to <b>Escherichia coli</b> bacteria. E coli ferments the sugars in the chocolate waste, which generated organic acids so toxic to the bacteria that they began converting formic acid to hydrogen.
| |
| - | <a href="http://environment.about.com/od/renewableenergy/a/chocolatefuel.htm">http://environment.about.com/od/renewableenergy/a/chocolatefuel.htm</a>
| |
| - |
| |
| - | -<b>Cellulose</b> waste can be converted to energy by using enzyme <b>cellulase</b>. The gene that codes for cellulase has been isolated and grown in large quantities by E. coli. A number of photosynthetic bacteria, nonphotosynthetic bacteria, cyanobacteria, and green, red, and brown algae produced the enzyme <b>hydrogenase</b>, which is necessary to make hydrogen. <a href="http://www.accessexcellence.org/RC/AB/BA/Future_Fuel.php">http://www.accessexcellence.org/RC/AB/BA/Future_Fuel.php</a> (Text by Yuanwei)<br>
| |
| - |
| |
| - | <h2>Feather-Eating Bacteria</h2>
| |
| - |
| |
| - | <b>Bacillus licheniformis</b> strain PWD-1 breaks down feathers into a feather-lysate compound. Feather-lysate provides a low-cost, highly digestible protein source for livestock feed. Bacillus has also been shown to secrete a <b>keratinase</b> enzyme that hydrolyzes proteins such as collagen, elastin, and keratin. Potential application in breakdown of livestock carcasses. The gene encoding the enzyme keratinase of Bacillus licheniformis is '''kerA'''.
| |
| - | <a href="http://www.accessexcellence.org/RC/AB/BA/The_Smell_of_Wealth.php"> http://www.accessexcellence.org/RC/AB/BA/The_Smell_of_Wealth.php</a>,
| |
| - | <a href="http://aem.asm.org/cgi/content/abstract/61/4/1469">"http://aem.asm.org/cgi/content/abstract/61/4/1469</a> (Text by Yuanwei)<br>
| |
| - |
| |
| - |
| |
| - | <h2>turning C3 plants into C4 plants</h2>
| |
| - | <b>problem</b>: How to make C3 plant operating in sunny and arid areas or how to reduce photorespiration<br>
| |
| - | <b>solution</b>: Create a bacteria which penetrates plant cells, creates high concentration of HCO<sub>3</sub><sup>−</sup> and packages it into vesicles, inactive Carbonic anhydrase is added to the vesicles, releases vesicles with chloroplast localisation signal, releases vesicles into the chloroplast, upon fusion CA is activated and changes HCO<sub>3</sub><sup>−</sup> into carbon dioxide, which is then highly concentrated in a chloroplast and reduces rate of O<sub>2</sub> binding to the Rubisco simply by increasing concentration of CO<sub>2</sub>.<br>
| |
| - | Chassis: E.coli or Sinorhizobium meliloti<br>
| |
| - | <br>
| |
| - | Bacterial infection: Nod factors<br>
| |
| - | <br>
| |
| - | Bacteria of Rhizobium spp. are capable of infecting a plant and forcing it to develop an extra organ - Nodule, where these bacteria then intracellularly (a bit like organelles) reside. They do this to develop a mutualistic relationship with plant. We could use this mechanism of infection and acceptance by using the entire "Nod box" a cluster of genes involved in signalling to the plant to allow entry through the specially deformed root (induced by the Nod factors) or by crack entry. Each of the two mechanisms involves plant release of the flavonoids in the first place to trigger the Nod factors in the first place.<br>
| |
| - | <br></html>
| |
| - | [[File:Rhizobium.gif]]<html><br>
| |
| - | <br>
| |
| - | <b>problems: </b><br>
| |
| - | -A lot of plants do not have Nod factor receptors, as wild type Rhizobium infects only legumes, so we would have been restricted to legumes as well. Also there is specificity among different Nod factors and their receptors on the plants meaning that not every Nod box containing bacteria could infect every plant. <br>-In theory inserting a whole "Nod box" of genes into E. coli should enable E.coli to function in relation to the plant much in the same way as Rhizobium does, however we can not be sure of that, even though there is evidence that some genes in Rhizobium (NodD) have orthologues in E. coli (glmS).<br>
| |
| - | -Plant accepts Rhizobium as a symbiont and expects to get something from it, therefore if we were to use Rhizobium as chassis we could leave the initial nitrogenase function intact, however there might be a problem using E. coli as it would not be capable of fixing nitrogen the plant might not accept its infection thread.<br> -Rhizobium forces plant to form nodule on the root, however ideally we would want to set up infection into the leaves. Maybe possibility to send vesicles through the xylem to the leaves, however vesicles would face problem of crossing plant cell wall.<br><br><b>Accumulation of HCO<sub>3</sub><sup>−</sup> and packaging into the vesicles: CaA and carboxysome </b><br>
| |
| - | A lot of cyanobacteria / algae, use specialised carboxysomes to accumulate HCO<sub>3</sub><sup>−</sup> through a number of HCO<sub>3</sub><sup>−</sup> transporters and carbon dioxide converting enzyme Carbonic anhydrase which performs interconversion of CO2 and HCO<sub>3</sub><sup>−</sup>. Different genes in C. reinhardtii (cupA, cupB) act as transporters of CO2 and automatically convert it to HCO<sub>3</sub><sup>−</sup>. There is a number of other transporters utilised by cyanobacteria, but these just transport HCO<sub>3</sub><sup>−</sup><br>
| |
| - | and do not convert it to CO2, and therefore are not useful to us. Then a number of genes involved in carboxysome production would have to be included in the chassis as well. Also normal carboxysome in a cyanobacterium contains a number of other protein products to convert CO2, however these are not necessary as carbon fixation would be performed by the plant itself. Finally a CaA - carbonic anhydrase converting HCO<sub>3</sub><sup>− </sup> to CO2 would be included, also Cso3 a Carbonic anhydrase embedded in the carboxysome membrane would be present.<br>
| |
| - | </html>
| |
| - | [[File:Carbonic_anhydrase.jpg]]<html><br></html>
| |
| - | [[File:carboxysome_pathway.jpg]]<html><br>
| |
| - | However it needs to be inactive within the carboxysome/vesicle and active only upon entry into chloroplast. Therefore possible fusion protein with 3 domains could be created containing CA on the inner end, then transmembrane subunit and a transit/fusion peptide targeting it to the chloroplast. Upon fusion into chloroplast the fusion protein would be cleaved and CA would become active.<br>
| |
| - | <br>
| |
| - | <b>problems:</b><br>
| |
| - | -Creation of carboxysome ( a whole "organelle") within a chassis not previously having any.
| |
| - | <br>
| |
| - | -Creating vesicles out of carboxysome, which would not release any of its content out into bacterial cytoplasm (whole compartmentalisation would not work)
| |
| - | <br>
| |
| - | -This also raises a question of what concentration of HCO<sub>3</sub><sup>−</sup> can be transported within one vesicle, if the concentration is too low it will not function.<br><br><b>Transport of vesicles from bacteroid into the chloroplast: OMV</b><br>
| |
| - | Could be largely based on the OMV-outer membrane transport, which has been worked out by igem team paris 2009. However a number of outer-transit/fusion peptides would have to be different to ensure targeting towards chloroplast and succesful fusion into the chloroplast.<br><b>
| |
| - | problems:</b> <br>
| |
| - | -Usual transit peptide used for fusion protein targeting from cytoplasm into chloroplast (5kDa Rubisco subunit) might not work in targeting of the wholve vesicle into the chloroplast.
| |
| - | <br>-Previous igem team have developed OMV to transport proteins from cytoplasm to another bacteria. In this situation however we would use OMV to transport concentrated solution from carboxysome - "organelle", therefore the OMV itself might not work on our setup.<br><b>Ideal solution:</b> Engineer carboxysome with Carbonic anhydrase within plants (possibly within chloroplast) and use it to generate high CO2 concentration.<br>
| |
| - | <b>References</b>: Moroney, J.V. & Somanchi, A., (1999). How Do Algae Concentrate CO2 to Increase the Efficiency of Photosynthetic Carbon Fixation? Plant Physiology, 119 (1), 9 -16. <br>
| |
| - | Goodsell a S. Dutta, “Carbonic Anhydrase”, RCSB Protein Data Bank (january, 2004), http://www.pdb.org/pdb/101/motm.do?momID=49. <br>
| |
| - | Nod factor interaction picture taken from: http://www.glycoforum.gr.jp/science/word/saccharide/SA-A02E.html
| |
| - |
| |
| - | </html>
| |
| - |
| |
| - | <b>Rebekka Bauer</b>
| |
| - | <br><br>
| |
| - | - I first looked at biological synthesis of isorhy, which may be used to treat Parkinson's and IBS. I stopped looking at this due to the reasons outlined by Frank.
| |
| - | <br><br>
| |
| - | Food fermentation (food waste conversion/increasing shelf life):<br>
| |
| - | - Thermoanaerobacterium thermosaccharolyticum can be used to convert food waste into hydrogen (O-Thong, S., Prasertsan, P., Karakashev, D., & Angelidaki, I. (2008). Thermophilic fermentative hydrogen production by the newly isolated thermoanaerobacterium thermosaccharolyticum PSU-2. International Journal of Hydrogen Energy, 33(4), 1204-1214. and Shin, H. S., & Youn, J. H. (2005). Conversion of food waste into hydrogen by thermophilic acidogenesis. Biodegradation, 16(1), 33-44.) However, I could not find information on the genes responsible for this and they may not have been identified yet.
| |
| - | <br><br>
| |
| - | - Lactic acid bacteria can be used in food fermentation as "starter cultures". They produce several compounds and help extend the shelf life of the product
| |
| - | (Leroy, F., & De Vuyst, L. (2004). Lactic acid bacteria as functional starter cultures for the food fermentation industry. Trends in Food Science & Technology, 15(2), 67-78.)
| |
| - | <br><br>
| |
| - | - Lactic acid bacteria can produce a compound that fights Staph aureus, increasing food safety (Cavadini, C., Hertel, C., & Hammes, W. P. (1998). Application of lysostaphin-producing lactobacilli to control staphylococcal food poisoning in meat products. Journal of Food Protection 174;, 61(4), 419-424.)
| |
| - | </html>
| |
| - |
| |
| - | <html>
| |
| - | <b>Atipat Patharagulpong</b>
| |
| - | <br><br>
| |
| - | Transportable Dengue Mosquitoes “simulated Nepenthes”
| |
| - | <br><br>
| |
| - | Engineering bacteria which could be put into the water container in order to attract, trap and kill the dengue mosquitoes and therefore decoy the mosquito away from biting you.
| |
| - | <br><br>
| |
| - | Overview
| |
| - | <br>
| |
| - | - Dengue virus (RNA) : fever, haemorrhage, shock, organ disfunction
| |
| - | <br>
| |
| - | - Problems : no vaccine, difficult to engineer vaccine, acute but at the same time chronic
| |
| - | <br>
| |
| - | - Vectors : Aedes aegypti >> target!!!
| |
| - | <br>
| |
| - | - Why? : Lay egg at night (specific time), fragile, is the only 1 type of vector
| |
| - | <br><br>
| |
| - | Engineering bacteria
| |
| - | <br>
| |
| - | Module 1 : Allurement
| |
| - | <br>
| |
| - | - Odour > lactic a, octenol, NH3 > LDHB, LOX, AOS, GDH http://en.wikipedia.org/wiki/Aedes_aegypti, http://chemse.oxfordjournals.org/content/30/2/145.full
| |
| - | <br>
| |
| - | - Light > orange fluprescent protein (600 nm)http://journals.fcla.edu/flaent/article/view/75460
| |
| - | <br>
| |
| - | Module 2 : Entrapment
| |
| - | <br>
| |
| - | - Surfactant > Flavobacterium > GLD, https://colloque.inra.fr/flavobacterium/content/download/.../28Hunnicut.pdf
| |
| - | <br>
| |
| - | Module 3 : Torment
| |
| - | <br>
| |
| - | - Egg and Larva > Bacillus thuringiensis > Cry, Cyt, Chi
| |
| - | <br>
| |
| - | - Adult > Geranyl acetone > Populus trichocarpa > POPTRDRAFT_596199, http://www.ncbi.nlm.nih.gov/pubmed/20127888
| |
| - | </html>
| |
| - |
| |
| - | <html>
| |
| - | <font size= "5"><b>Frank Machin</b></font>
| |
| - | <br>
| |
| - | The following is a list of roles that people chose to be in charge of:
| |
| - | <br>
| |
| - | Rebekka - Stocks supplies protocols
| |
| - | Nick - Human Practices
| |
| - | Ming - Collaboration
| |
| - | Yuanwei - Wiki
| |
| - | Frank - Software/hardware
| |
| - | Chris - Parts characterisation
| |
| - | Nikki - Cloning
| |
| - | Si - Modelling
| |
| - | Nina - Photo/Media/Film
| |
| - | <br>
| |
| - | <br>
| |
| - | • Fixed wiki - get everyone's formatting to match
| |
| - | - Relocate Notebook Page
| |
| - | - Explain HTML
| |
| - | <br>
| |
| - | • Returned Alan's phone - £20 for the iGEM kitty - books/events/beer etc.
| |
| - | <br>
| |
| - | • I am also done chairing!! - Rebekka now takes over
| |
| - | <br>
| |
| - | <br>
| |
| - | <b>Wiki Rules</b>
| |
| - | <br>
| |
| - | 1) You do not talk about wiki editing<br>
| |
| - | 2) You do not talk about wiki editing<br>
| |
| - | 3) All files are to be uploaded with the name : ICL_Exact_Description_of_File_with_a_number <br>
| |
| - | 4) Keep the formatting the same on every page <br>
| |
| - | 5) DO NOT change content that someone else has uploaded without talking to them first<br>
| |
| - | 6) Please always upload in HTML, not Wiki Formatting<br>
| |
| - | 7) Try and make your content look like the other content on the page<br>
| |
| - | <br>
| |
| - | <br>
| |
| - | Art Students from the Royal College of Arts came in to give us all a talk about their work, and we would talk about ours in order to come up with a cool idea.
| |
| - | <br>
| |
| - | <b>Synopsis of BioArts</b>
| |
| - | <br>
| |
| - | <b>Koby</b> - Transferring life/soul into a project<br>
| |
| - | - Growing furniture parts
| |
| - | <br>
| |
| - | <b>Pei-Ying</b> - Vaccine Beauty - smallpox can cause scarring - scar art - get newest virus to be infected by so that you are immune to the latest version
| |
| - | • Minimal Nano-Diet Guide - transparent food
| |
| - | • Use Genetic code as a way to protect data by encoding their voices
| |
| - | <br>
| |
| - | <b>CJ</b> - SOBAgate - What happens if you modified people to react differently in response to feelings of greed, lust or anger
| |
| - | • lust - all the blood goes to genitals and they pass out
| |
| - | • anger - voice becomes squeaky
| |
| - | • greed - gut bacteria release aspirin like chemicals so eating cake results in rashes, bleeding and bruises
| |
| - | <br>
| |
| - | <b>Older artists</b>
| |
| - | <br>
| |
| - | <b>Oron Catts</b> - all about half-living/half-dead tissue
| |
| - | • sets up a lab in a gallery
| |
| - | • Pig wings - growing wings from pigskin
| |
| - | • Half-living worry doll - people write worries into a computer and this altered the nutrients available to the doll
| |
| - | • Victimless meat - grew little steaks
| |
| - | • Victimless leather - grew a tiny leather jacket - got shut down due to contamination/fear
| |
| - | <br>
| |
| - | <b>Orlan</b> - Saint Orlan - did plastic surgery as performance - was interested in how her beauty affected other people
| |
| - | • apparently gives amazing talks
| |
| - | • harlequin suit inspired by Catts - grown triangles of skin from diff. races and animals and made them into a technicolour coat
| |
| - | <br>
| |
| - | <b>Newer artists:</b>
| |
| - | <br>
| |
| - | <b>David Benque</b> - singing flowers<br>
| |
| - | • designed a range of plants that would make sounds<br>
| |
| - | • so diff. plants at diff. times of year would be musical<br>
| |
| - | • ie modified bacteria makes gas so flower would inflate and then the air would escape and make a sound - a fart sound<br>
| |
| - | • saying that synthetic biology doesn't have to be scary<br>
| |
| - | <br>
| |
| - | <b>Tuur van balen</b><br>
| |
| - | • Pigeon d'or - modify pigeons so that they shit soap<br>
| |
| - | • designed objects that people would have in that reality<br>
| |
| - | • leech - adapt how melancholy you felt using certain yeasts that affect your mood - leech assesses how melancholy you are and processes the blood and introduces endorphins<br>
| |
| - | • then blend leech and eat it<br>
| |
| - | <br>
| |
| - | <br>
| |
| - |
| |
| - | <b>Ideas Discussion</b>
| |
| - | <br>
| |
| - | <b>Snake Antivenom</b> - get lots of bacteria with a hypermutagenic region in a plasmid that makes a protein on the cell surface and then select for the proteins and therefore for the genes by testing the binding affinity of the cell surface markers and therefore the bacteria<br>
| |
| - | - This can then be used to select for the protein/proteins that have the greatest binding affinity to the venom proteins and so an optimum mixture of antivenom proteins can be made
| |
| - | <br>
| |
| - | <b>Melatonin</b> - Not good as its just expressing something
| |
| - | <br>
| |
| - | <b>Chris' Vampires</b> - More research needed - ask an expert on clots
| |
| - | <br>
| |
| - | <b>Si Chen's Leaves</b> - Bit of a chemistry project - cellulases are tricky to work with
| |
| - | <br>
| |
| - | <b>Yuanwei</b> - Waste is too vague, but a nice idea - possibly put on back burner
| |
| - | <br>
| |
| - | <b>Nick</b - Awesome idea, some of it done before by Pam Silver (sp?) - put on back burner because it is so cool
| |
| - | <br>
| |
| - | <b>Rebekka</b> - dismiss food waste one as it is too vague<br>
| |
| - | • bacteria that can detect and fight staph aureus would be useful - may need more research - so it was put on the back burner
| |
| - | </html>
| |
| - | <html>
| |
| - | <br><br><b>Christopher Schoene</b><br><br>
| |
| - |
| |
| - | Today we started with a briefing from Frank where the main action points of the day were discussed. These included creating a cleaner and more standardized wiki code as to ease future editing as well as determining which projects that we had each researched the previous day could be a viable project. We also agreed to only use HTML code when writing in the wiki. <br><br>
| |
| - | We spent around an hour or two clearing up and getting to know the HTML language. At around 11, three students from the RCA came to talk about their projects. Coby presented his ideas of growing furniture as well as trying to recreate his grandfather's psyche in a mouse. Pei-Ying presented her projects; using smallpox vaccines as a form of prevention against future terrorist attacks, nano diets where all the basic dietary requirements (vitamins, monosaccharides, amino acids, etc) are measured to the exact amount needed and a strange device that would store the voice of another human being if you were to touch them. CJ introduced us to several artists like Orlan and their ideas of which I personally found the ideas of growing leather/meat and using pigeons to clean our buildings as the most interesting and plausible ideas. <br><br>
| |
| - | After this presentation we discussed our ideas with the students of the RCA over a lunch at Eastside. I presented the idea I had decided to research but no further progress could be made on the vampiric blood. We continued brainstorming and decided that this idea might be possible though the use of vesicles, however, it is no longer a priority project. <br><br>
| |
| - | We have decided to split the team into 3 teams. Nicola, Nikki and Rebekka will be working on the prodigiosin pigment. Si, Nina and Yuanwei will be working on trying to improve on a bacterial hard drive that has already been tried in past iGEM projects. Frank, Ming and I will be working on the anti-venom idea. We will also try to use a little time to come up with more problems we could try to solve tomorrow. <br><br>
| |
| - | </html>
| |
| - |
| |
| - | <html>
| |
| - | <b>Rebekka Bauer</b><br>
| |
| - | Action points:<br>
| |
| - | -bios on the wiki<br>
| |
| - | -sci-fi meeting<br>
| |
| - | -characterisation talk<br>
| |
| - | -come up with more ideas<br>
| |
| - | -do more research on anti-venom and prodigiosin<br>
| |
| - |
| |
| - | <br><br>
| |
| - | Sci-Fi prodigiosin ideas (developed with Nick Kral and CJ from the RCA):<br>
| |
| - | -use prodigiosin (red pigment) as the new "colour of health" (know something is sterile rather than assume it is)<br>
| |
| - | -possible future uses: in decontamination/ as a "panic room"/ sterile hospice<br>
| |
| - | -possible future products: hand gel, clothing (e.g. protective suits in bioreactor plants), decontamination paint (in hospitals etc)<br>
| |
| - | -actual uses: anti-cancer (could be in a red drip, red pill?), anti-malarial (drug verification because pigment colour is hard to fake)<br>
| |
| - | Eventually, this idea was scratched because optimising the production pathway does not contain enough synthetic biology. In addition, the compound is immunosuppressive (http://pubs.rsc.org/en/Content/ArticleHtml/2008/CC/b719353j) and would therefore be disadvantageous to normal people. Many of the envisaged applications would only work with less problematic analogues of prodigiosin.
| |
| - | <br><br>
| |
| - |
| |
| - | Brainstorming:<br>
| |
| - | Venom and BAS ideas to be presented on Friday!<br>
| |
| - | -desertification (overdone already)<br>
| |
| - | -thermophiles (make them express melanin so they can be heated up by the sun, saving energy)<br>
| |
| - | -cell-cell signal transduction (can be used as inhibition or activation)<br>
| |
| - | -desalination (commercial membranes are probably more efficient)<br>
| |
| - | -data storage in bacteria (use DNA to encode information has already been done but it might be useful to come up with a new way of retrieving the information. Storing data in RNA might be more efficient)<br>
| |
| - | -ocean metals (retrieving valuable materials from sea water, main problem: materials are only present at really low concentration and might be hard to retrieve)
| |
| - | -cross-linking of hair to something useful<br>
| |
| - | -dictostylium<br>
| |
| - | -using melanin for heat production from sound in bacteria. The heat could then be converted into an output, producing sound sensitive bacteria. Is melanin really able to detect sound??<br>
| |
| - | -modifying silk worms?<br>
| |
| - | -radiotrophic fungi (fungi that use gamma radiation to produce ATP - the pathway could be used in E. coli to absorb radioactivity but the exact pathway does not seem to be known (Wikipedia))<br>
| |
| - | -serum bile acid as a biomarker of liver problems in pregnancy<br><br>
| |
| - |
| |
| - | Research for venom:<br>
| |
| - | organise slides into problem, specifications needed to tackle problem, how to achieve specifications<br>
| |
| - | -venom chosen: Asian cobra (one of the most common ones)<br>
| |
| - | -Ming: summarise problem and specifications needed<br>
| |
| - | -Chris: look at shark antibodies<br>
| |
| - | -Nikki: look at in vivo mutagenesis (PCR mutagenesis would be too tedious)<br>
| |
| - | -Frank: selection (FACS with GFP?)<br>
| |
| - | -Rebekka: genetic circuit (detection mechanism - two component system?, suicide mechanism for cells that do not detect venom)
| |
| - |
| |
| - |
| |
| - | <html>
| |
| - | <p>
| |
| - | <p>
| |
| - | <DIV style="TEXT-INDENT: -7.1pt; MARGIN: 0cm 0cm 0pt 7.1pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 11.0pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=5 face=Calibri><STRONG></STRONG></FONT></SPAN></SPAN></FONT> </DIV>
| |
| - | <DIV style="TEXT-INDENT: -7.1pt; MARGIN: 0cm 0cm 0pt 7.1pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 11.0pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=5 face=Calibri><STRONG>Si, Nina, Nick and Yuanwei</STRONG></FONT></SPAN></SPAN></FONT></DIV>
| |
| - | <DIV style="TEXT-INDENT: -7.1pt; MARGIN: 0cm 0cm 0pt 7.1pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="FONT-SIZE: 14pt; mso-bidi-font-size: 11.0pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT face=Calibri></FONT></SPAN></SPAN></FONT> </DIV>
| |
| - | <DIV style="TEXT-INDENT: -7.1pt; MARGIN: 0cm 0cm 0pt 7.1pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="FONT-SIZE: 14pt; mso-bidi-font-size: 11.0pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-SIZE: 14pt; mso-bidi-font-size: 11.0pt" lang=EN-US><FONT face=Calibri>morning:<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></FONT></SPAN></B></FONT></DIV>
| |
| - | <P style="TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>brain storming:</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l1 level1 lfo3" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>meeting with RCA people </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l1 level1 lfo3" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>presenting the DNA hard drive idea</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -21.25pt; MARGIN: 0cm 0cm 0pt 35.45pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>1.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>use DNA sequence as a medium to store information</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 36.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 3.5" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>DNA base - quaternary bit - original text </FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -21.25pt; MARGIN: 0cm 0cm 0pt 35.45pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>2.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>put “tag in” information (i.e some specific base pairs as “prototypes”) to classify the information</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -21.25pt; MARGIN: 0cm 0cm 0pt 35.45pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-bidi-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>3.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>writing functions in programming language with DNA sequences, use DNA as the function variables</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 35.9pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 3.42" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt -0.1pt; mso-para-margin-left: -.01gd" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>- Sci-Fi:</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -10.5pt; MARGIN: 0cm 0cm 0pt 10.5pt; mso-char-indent-count: -1.0" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri> a. in the future, a bacteria charm/necklace can be made to store and carry the information, such as exam syllabus, genetic disease history, family photos, etc</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -10.5pt; MARGIN: 0cm 0cm 0pt 10.5pt; mso-char-indent-count: -1.0" class=MsoNormal><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN lang=EN-US> b. different coding methods and types of bacteria can be chosen by the clients for different levels of security needs ,(some high risky information can be store in </SPAN><SPAN class=st1><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US>Bacillus anthraci for military use)</SPAN><SPAN lang=EN-US><o:p></o:p></SPAN></SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: -10.5pt; MARGIN: 0cm 0cm 0pt 10.5pt; mso-char-indent-count: -1.0" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000> c. data can also be stored in E.coli in the human digestive system, it can be erased by intaking antibiotics<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 36.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 3.5" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l1 level1 lfo3" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri>practical problem:<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>we need a bacteria platform to carry out the operation of the data<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>(I.e: bio-compiler? bio-CPU?) <o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 15.75pt; mso-para-margin-left: 1.5gd" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>a compiler consists of sets of programs and logic relations, it is theoretically workable, but obviously too difficult to do as a ten-week project<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 36.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 3.5" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -7.1pt; MARGIN: 0cm 0cm 0pt 7.1pt; mso-char-indent-count: 0; mso-list: l1 level1 lfo3" class=MsoListParagraph><FONT color=#000000><SPAN style="FONT-SIZE: 14pt; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-SIZE: 14pt; mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT face=Calibri>afternoon:<o:p></o:p></FONT></SPAN></B></FONT></P>
| |
| - | <P style="TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>brain storming:<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 5.25pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: .5" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri>since the bio-compiler idea is abandoned, we thought about other ways to store data:<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri>ROM memory<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 15.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 1.5" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>8x8 gird to store 64 bits of data<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 15.75pt; mso-para-margin-left: 1.5gd" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>the bacteria interaction can be modified to give to outputs, which indicates the two binary states (0 or 1) <o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><FONT size=3><FONT face=Calibri>JK flip-flop or synchronized counter<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><FONT size=3><FONT face=Calibri>7-segment display<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 15.75pt; mso-para-margin-left: 1.5gd" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>one bacterium -four input channels-each channel with two states (0 or 1)-nine outputs to give nine numbers (0 to 9)- control the corresponding segments to display the number<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><FONT size=3><FONT face=Calibri>bacterial minesweeper<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 15.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 1.5" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>an inhibitor can be considered as a ”mine”<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 15.75pt; mso-para-margin-left: 1.5gd" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>the main problem is that secondary diffusion is very difficult to control. a mass transfer equation must be modeled for each individual square<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><B style="mso-bidi-font-weight: normal"><SPAN style="COLOR: #7030a0; FONT-SIZE: 12pt; mso-bidi-font-size: 10.5pt" lang=EN-US><FONT face=Calibri><FONT color=#9900ff>Bile Acid Sensor:<o:p></o:p></FONT></FONT></SPAN></B></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US><FONT size=3><FONT face=Calibri>the idea came up with SI’s final year project<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><EM><SPAN style="COLOR: windowtext; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN></EM><FONT size=3><FONT face=Calibri><SPAN style="mso-bidi-font-size: 10.5pt" lang=EN-US>a biosensor can be produced for daily home use to detect the bile acid </SPAN><SPAN style="COLOR: #0d0d0d; mso-bidi-font-size: 10.5pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US>concentration level in blood to prevent a series of liver diseases, especially the </SPAN><SPAN><SPAN style="COLOR: #0d0d0d; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US>Intrahepatic cholestasis of </SPAN>pregnancy </SPAN><SPAN><SPAN style="COLOR: #0d0d0d; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US>(</SPAN>ICP)<o:p></o:p></SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><SPAN><FONT color=#000000><SPAN style="mso-list: Ignore"><EM><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></EM></SPAN><FONT size=3><FONT face=Calibri>the basic concept behind this sensor:<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 15.75pt; mso-para-margin-left: 1.5gd" class=MsoNormal><SPAN style="COLOR: #0d0d0d; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>bile acid - enzyme binding with the acid molecules – promoter – triggering the FXR gene – production of GFP<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -14.2pt; MARGIN: 0cm 0cm 0pt 14.2pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><SPAN><FONT color=#000000><SPAN style="mso-list: Ignore"><EM><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></EM></SPAN><FONT size=3><FONT face=Calibri>GFP is normally used as an indicator of the bio-sensor<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 15.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 1.5" class=MsoNormal><SPAN style="COLOR: #0d0d0d; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>the main problem is that the fluorescent intensity is very hard to quantified for a home-user<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -15.75pt; MARGIN: 0cm 0cm 0pt 15.75pt; mso-char-indent-count: -1.5" class=MsoNormal><SPAN style="COLOR: #0d0d0d; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>- <SPAN style="mso-spacerun: yes"> </SPAN>being inspired by the cosmetic skin colour sample card , we can make a sample card of fluorescence to give the rough concentration level of bile acid<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -15.75pt; MARGIN: 0cm 0cm 0pt 15.75pt; mso-char-indent-count: -1.5" class=MsoNormal><SPAN style="COLOR: #0d0d0d; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>- <SPAN style="mso-spacerun: yes"> </SPAN>a threshold value is required to tell the patient when their blood bile acid level is dangerous and may need a medical treatment<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -15.75pt; MARGIN: 0cm 0cm 0pt 15.75pt; mso-char-indent-count: -1.5" class=MsoNormal><SPAN style="COLOR: #0d0d0d; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>-<SPAN style="mso-spacerun: yes"> </SPAN>therefore, we will modify the linear relationship between bile acid concentration and GFP intensity level into a Hill system using Hill equation to find the threshold value<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN><FONT size=3><FONT face=Calibri><FONT color=#000000>- <SPAN style="mso-spacerun: yes"> </SPAN>also, we may use colour indicator instead of GFP (light indicator) <SPAN style="mso-spacerun: yes"> </SPAN><SPAN style="mso-spacerun: yes"> </SPAN><SPAN style="mso-spacerun: yes"> </SPAN><o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN style="COLOR: #0d0d0d; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 242" lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | </html>
| |
| - | <html><br><br><b>Christopher Schoene</b><br><br>
| |
| - | Today we discussed the anti-venom idea with Koby (the RCA student that had arrived). He helped us expand the idea to maybe provide protection against viruses as well. We even developed the idea to use a seasonal hand wash containing the purified antibodies from the season's viruses in order to create a world where a handshake would be more than just a form of greeting but also a way to pass on immunity.<br><br>
| |
| - |
| |
| - | After the brain-storming session we had a talk from Chris about characterisation giving me a glimpse into what I would be expecting in the weeks after the project has been pinned down on a single idea. We currently have two running ideas; the anti-venom and a bile acid sensor. We have split off into two teams and each is working hard in order to build a system that the professors might agree to this Friday at 3:30pm. The deadline is approaching and we still require 2 more possible projects to present to the professors. I will work with my team to complete the anti-venom idea tomorrow and I will try to research a way to improve upon the idea of the use of yeast in water retention by making the express mucins.<br><br>
| |
| - |
| |
| - | RCA sci-fi story ideas: <br>
| |
| - | Nuclear winter leaving people without immune systems. Use external immune system to save everybody? <br><br>
| |
| - | Synthetic life can only use certain amino acids, firewall? <br>
| |
| - | Biocomputers where man and machine are converged closer together. <br>
| |
| - | Floppy disk baby? <br>
| |
| - | Mock news articles (Times, science article, tabloid), comic strips (simplified version of our project), documentary type video?, <br>
| |
| - | Terrorist attacks<br><br>
| |
| - | <b>Characterization presentation by Chris:</b> <br><br>
| |
| - | in vivo presentation<br>
| |
| - | Timer vs. switch. need to know characteristics of parts. <br>
| |
| - | How to characterise<br>
| |
| - | Look at individual parts. What goes in, what goes out. What function is carried out. <br>
| |
| - | What specifically do you want to characterise. <br>
| |
| - | Terminator, core-promoter, RBS, reporter, coding region. <br>
| |
| - | Terminator requires several different characterizations. <br>
| |
| - | Place promoter, coding region into an expression circuit with a reporter. <br>
| |
| - | Standards are only existant for promoters. How strong promoters are. <br>
| |
| - | Canton paper 2008. Base characteristics that you need to know about an inducible promoter. <br>
| |
| - | How responsive (transfer function of response), dynamic? (output) <br>
| |
| - | All relative to J23101. <br>
| |
| - | Synthesis rate, number of cells and divide your promoter output with standard which gives you a value relative to J23101. RPU (relative promoter unit) <br>
| |
| - | RBS calculator gives you a value to how strong it is. Need to debug yourself. <br>
| |
| - | Hard to characterise until we know what we want to do. <br>
| |
| - | Plate readers look at OD, fluorescene, luminescence. <br>
| |
| - | Individual cells analyzed for GFP and RFP. <br>
| |
| - | Chris works on methods to make it more high-throughput (automates to make faster). <br>
| |
| - | Won't consider optimizing something unless it worked twice on the assays. <br>
| |
| - | Fluorescence doesn't give use pinpoint accuracy. Can't be measured really well, only bulk events and not specific events. <br>
| |
| - | Enzymatic activity more done in vitro. <br>
| |
| - | You're working with factories that work depending on what they're in. <br>
| |
| - | Can find Chris though James at any time. <br>
| |
| - | Make sure positive and negative control will work. <br><br>
| |
| - | <b>Antibody research:</b> <br><br>
| |
| - | -Single-domain antibodies such as the nurse shark derived IgNAR and the camelid derived VHH have been used for many purposes and have recently started to gain popularity among the scientific community. <br>
| |
| - | -Contain CD3 loop that gives these Ig's an advantage when looking for cryptic viral epitopes. However, contain ten epitope copies and might still infect. Solved by increasing their mass. <br>
| |
| - | -Both of these Ig's are stable enough to be administered orally. <br>
| |
| - | -Orally administered transformed lactobacilli were used to administer anti-TNF Ig. <br>
| |
| - | -Small dimensions of VHHs allow it to be easily tagged. <br>
| |
| - | -Lactobacilli have been engineered that produces VHH's at a rate fast enough to prevent infection by p2 bacteriophage. Possibly use lactobacillus for screening and E. coli for secretion? <br>
| |
| - | -VHH's and IgNAR's have been effective in detecting poliovirus and inhibiting its replication in vitro, as well as preventing the assembly and secretion of hepatitis B. Possible to use VHH's as intrabodies vs. HIV-1? <br>
| |
| - | -N-glycosylation increases stability. <br>
| |
| - | -Studies demonstrated that pre-immune libraries can be used for rapid generation of Ig's against a large number of harmful antigens. Troublesome low sensitivity overcome by using phage-displayed instead of purified antibodies.[1] <br><br>
| |
| - | <b>References:</b> <br><br>
| |
| - | <a href=http://ultr23.vub.ac.be/ultr/pub/pdfs/98.pdf>[1]</a>Ario de Marco, “Biotechnological applications of recombinant single-domain antibody fragments,” Microbial Cell Factories 10, no. 1 (2011): 44.
| |
| - | </html>
| |
| - |
| |
| - | <html>
| |
| - | <b>Frank Machin</b>
| |
| - | - A method is needed to sort cells by their ability to bind the venom proteins<br>
| |
| - | - One such method would be to have the cells secrete their anti-venom proteins and then flood the cells with venom. The best cells would survive and the weak ones would be killed. However, this may cause the production of proteins that bind the venom components that are less dangerous such as phospholipases and oxidases. It would be more important for the anti-venom to inhibit the neuro-muscular disruptive proteins<br>
| |
| - | <br>
| |
| - | - One effective method would be to use Fluorescence Activated Cell Sorting, which is able to sort cells by their fluorescence. See: http://www.bio.davidson.edu/courses/genomics/method/FACS.html
| |
| - | <br>
| |
| - | - This would require a system that expresses a fluorescent reporter in response to the binding of venom proteins to the cell-surface proteins, but I cannot be too specific until I know how the anti-venom proteins are going to be expressed
| |
| - | <br>
| |
| - | - Yet another method would cause the death of any cells that do not bind to the venom with high enough affinity - it would be similar to the methods employed in T-cell selection in eukaryotic immune systems, but would be more tricky as it has to occur in a bacterium
| |
| - | <br>
| |
| - | - The ideal then, would be to have all the cells that have little or no binding affinity killed, and then those that do bind express GFP so that the fluorescence can be quantified and the binding can be rated
| |
| - | <br>
| |
| - | - Again, I'd need to understand the anti-venom proteins before I could suggest any particular systems<br>
| |
| - | - Perhaps a second species of bacteria could be used to express the venom proteins on their surface, and come into contact with the anti-venom producing cells, causing contact-dependant stimulation, so that those that interact by the venom-antivenom complexes will be stimulated to divide whilst the remaining cells will potentially be killed
| |
| - | See: http://www.ncbi.nlm.nih.gov/pubmed/21085179
| |
| - | </html>
| |
| - |
| |
| - | <html>
| |
| - | <b>Nikki Kapp</b>
| |
| - | <br>
| |
| - | - we need a method for random mutagenesis of peptides to create high affinity binding proteins to the multiple components of venom<br>
| |
| - | - PCR based mutagenesis is namely used for site directed mutagenesis and has several biases that make it not ideal for random mutation<br>
| |
| - | - in vivo homologous recombination inherent to yeast can be exploited for protein mutagenesis<br>
| |
| - | (Pirakiticulr et al., 2010)
| |
| - | <br>
| |
| - | MAGE (multiplex automated genome engineering)<br>
| |
| - | See: http://www.nature.com/nature/journal/v460/n7257/fig_tab/nature08187_F4.html
| |
| - | - a method for large scale evolution of cells<br>
| |
| - | - has been used to optimize the 1-deoxy-d-xylulose-5-phosphate (DXP) biosynthesis pathway in E.coli for isoprenoid lycopene overexpression with a pool of synthetic DNA to modify 24 genes in the pathway creating > 4.3 billion combinatorial genomic variants per day (Wang et al., 2009<br>
| |
| - | - can do insertions, deletions and mismatches<br>
| |
| - | See: http://www.nature.com/nature/journal/v460/n7257/fig_tab/nature08187_F1.html
| |
| - |
| |
| - | </html>
| |
| - |
| |
| - | <html>
| |
| - | <b>Atipat Patharagulpong</b><br>
| |
| - | How can venom antibody be engineered with bacterial platform using synthetic biology?
| |
| - | <br><br>
| |
| - | Venom refers to varieties of toxins produced by certain types of animals. One of the most common
| |
| - | venoms are produced by snakes where 15% of 3,000 species of snakes are found poisonous. Snake
| |
| - | venom consists of proteins, enzymes, substances with a cytotoxins, neurotoxins and coagulants
| |
| - | <br><br>
| |
| - | Most snake envenomings and fatalities are found in South Asia, South East Asia and sub-Saharan Africa
| |
| - | with the high fatality rate of 125,000 deaths per annual. Among these India is reported the most cuased
| |
| - | by big 4 including Russell's viper, Indian cobra, saw-scaled viper, and the common krait. Indian cobra is
| |
| - | found the most famous and make the highest fatality rate (43%) in India and Southeast asia.
| |
| - | <br><br>
| |
| - | Indian cobra venom contains a potent post-synaptic neurotoxin which acts on the synaptic gaps of the
| |
| - | nerves, thereby paralyzing muscles, and in severe bites leading to acute respiratory failure or cardiac
| |
| - | arrest. The components of venom include lysis enzymes such as hyaluronidase which increase the
| |
| - | spread of the venom. Its toxicity is found one of the highest based on LD50 value in mice. Symptoms of
| |
| - | cobra envenomation can begin from 15 minutes to two hours after the bite, and can be fatal in less than
| |
| - | an hour.
| |
| - | <br><br>
| |
| - | Despite the advance in emergency therapy, antivenom is often only the effective treatment. In
| |
| - | treatment antivenom is injected into patient intravenously which could neutralize the toxin. Collecting
| |
| - | of antivenom is done by milking the venom and injected into the cattle. The subject will undergo
| |
| - | immune response where its antibody produced can be collected. This common method of obtaining
| |
| - | antivenom can tackle many toxins in the venom but however is considered unproductive since only
| |
| - | small amount of antivenom is produced from the animal blood which is due to complicated serum
| |
| - | purification process from the animal's serum. Waiting of animal recovery from venom also make its production quite slow and in several cases the animals die after injection.
| |
| - | <br><br>
| |
| - | Therefore bacteria should be introduced as a substituted platform utilizing synthetic biology to deal with the problems mentioned
| |
| - | above. Apart from existing characterised antivenom, other antivenoms could be more easily discovered
| |
| - | using the various mutagenesis of variable region of antivenom antibody. To develop this platform,
| |
| - | well known venom could be produced to test this platform. Indian cobra snake is therefore chosen
| |
| - | as the first target due to its generality, high toxicity and it is also one of the highest profile antivenom
| |
| - | discovered which could potentially save many victims from this fatal snakebite.
| |
| - | <br><br>
| |
| - | The way to engineer the bacteria is to mutagenise the shark antibody gene to allow different variable regions of the antibody to be expressed on the surface of the bacteria in different libraries. The venom is screened onto each plate of different bacteria libraries. The venom will bind to the right antibody and trigger the signal cascade which results in the expression of the fluorescence proteins which can be detected by FACs. machine. The bacteria that produces the antibody for the venom will be subjected to DNA sequencing which could be the platform for producing bacteria expressing antibody specific to the venom in the future.
| |
| - | <br>
| |
| - | </html>
| |
| - | <br>
| |
| - | <br>
| |
| - |
| |
| - | <html>
| |
| - |
| |
| - | <b>Frank Machin</b>
| |
| - |
| |
| - | So the method for the anti-venom generation begins as follows:<br>
| |
| - | <br>
| |
| - | 1:<br>
| |
| - | <br>
| |
| - | Take the venom proteins and bind biotin to either the C or N terminus so that it is able to be fixed to a large ferro-magnetic beads that are coated in streptavidin. Streptavidin has an extremely high affinity for biotin and the beads can be picked up with a neodynium magnet - so the bacteria with the 'antibody' on their surface that is able to bind to the venom proteins will be attached to the bead.
| |
| - | <br>
| |
| - | 2: <br>
| |
| - | <br>
| |
| - | The bacteria will have a plasmid that encodes a gene for a single-chain variable fragment, a fusion protein of the variable regions of the heavy and light chains of an immunoglobulin. This will be displayed upon the surface of the bacterium and will be on a plasmid that has a very mutagenic effect as described by Rebekka.
| |
| - | <br>
| |
| - | <br>
| |
| - | <br>
| |
| - | <b>Rebekka Bauer</b><br><br>
| |
| - | novel in vivo mutagenesis mechanism:<br>
| |
| - | -construct target genomic DNA with really strong promoter with retrovirus recognition sequence (R U5 PBS etc to ensure that only this is reverse transcribed)<br>
| |
| - | -transcribe into RNA using a crap RNA pol that introduces mutations<br>
| |
| - | -reverse transcribe into DNA using an overexpressed reverse transcriptase (overexpressed to ensure that this happens before DNA is degraded). The RT should be coupled to an inducible promoter to ensure that mutagenesis only takes place in bursts.<br>
| |
| - | -insert into genome via homologous recombination using an equivalent of infusion enzyme (maybe RecA?)<br>
| |
| - | </html>
| |
| - |
| |
| - | <b>Atipat Patharagulpong</b><br><br>
| |
| - | Contacts of people from RCA and LSE <br><br>
| |
| - | RCA<br>
| |
| - | - Pei-Ying Lin : peiying.lin@networkrca.ac.uk<br>
| |
| - | - Koby : yaacov.barhad@network.rca.ac.uk<br>
| |
| - | - CJ : charlotte@artforeating.com<br><br>
| |
| - | LSE<br>
| |
| - | - Alex Hamilton : r.a.hamilton@LSE.ac.uk <br>
| |
| - | - Claire MArris : c.marris@lse.ac.uk <br>
| |
| - | - Stephan Guttinges : s.m.guettinges@lse.ac.uk <br><br>
| |
| - |
| |
| - | Talk from LSE<br>
| |
| - | Things to consider in human practise<br>
| |
| - | Safety, Security, IP-intellectual property, ethical, biohacking, global fairness<br>
| |
| - | For Anti-venom project<br>
| |
| - | Safety : handling toxin in the lab, storage and transportation of toxins<br>
| |
| - | Security : produce specificity problem, antivenom target for particular person<br>
| |
| - | Patent : only the process obtaining product(antibody) but not the product itself, patent cost a lot of money <br><br>
| |
| - |
| |
| - | Idea : bacteria that solidify the soil in the presence of urea<br>
| |
| - | Sporosarcina pasteurii or Bacillus pasteurii from older taxonomies is a bacteria with the ability to solidify sand given a calcium and an organic nitrogen source through the process of biological cementation. This will be a good recycle of land waste, urea waste and a food waste.<br>
| |
| - | However solidification requires a high pH and produce toxic ammonium waste. Even though ammonia increase the pH this should be control using synthetic biology to model the right amount. ammonium can be subjected to other products which we are still searching for. Another application might be using ammonium produce to tighten the dye we made using the pigment which might allow the full house to be made easily from the brick.<br>
| |
| - | </html>
| |
| - |
| |
| - |
| |
| - |
| |
| - | <html>
| |
| - | <p>
| |
| - | <p>
| |
| - | <DIV style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN lang=EN-US><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p><FONT color=#000000 size=4 face=Calibri><STRONG>Si, Nina, Nick and Yuanwei</STRONG></FONT></o:p></SPAN></DIV>
| |
| - | <DIV style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN lang=EN-US><o:p> </o:p></SPAN></DIV>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-SIZE: 12pt; mso-bidi-font-size: 11.0pt" lang=EN-US><FONT face=Calibri><FONT color=#000000>MORNING:-<o:p></o:p></FONT></FONT></SPAN></B></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><B style="mso-bidi-font-weight: normal"><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></B></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><B style="mso-bidi-font-weight: normal"><SPAN lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>Serum Bile Acid Sensor Presentation:-<o:p></o:p></FONT></FONT></FONT></SPAN></B></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><B style="mso-bidi-font-weight: normal"><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></B></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>1.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>Background:</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><FONT size=3><FONT face=Calibri><SPAN lang=EN-US>Bile acids are 24-carbon steroids found in bile, </SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>which are subject to</SPAN><SPAN lang=EN-US> enterohepatic circulation </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>synthesized in liver and stored in gallbladder </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 15.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 1.5" class=MsoNormal><SPAN lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN style="mso-spacerun: yes"> </SPAN>helping in digestion and absorption of dietary fat and liposoluble vitamins </FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>bile acids = highly toxic </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN lang=EN-US>therefore their concentration </SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>must</SPAN><SPAN lang=EN-US> be tightly regulated</SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><FONT size=3><FONT face=Calibri><SPAN lang=EN-US>the level of bile acids is controlled t</SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>h</SPAN><SPAN lang=EN-US>rough a negative feedback system</SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>mediated by a nuclear bile acid receptor FXR. </FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN lang=EN-US>FXR </SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>is highly expressed </SPAN><SPAN lang=EN-US>in liver, intestine and kidney</SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB> cells</SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN lang=EN-US>it responds to bile acids an</SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>d has been shown to </SPAN><SPAN lang=EN-US>repress </SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>CYP7A1, a key gene</SPAN><SPAN lang=EN-US> associated with bile acid synthesis. </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-list: l0 level1 lfo1" class=MsoNormal><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><FONT size=3><FONT face=Calibri><SPAN lang=EN-US>Defects </SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>in</SPAN><SPAN lang=EN-US> bile acid </SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>homeostasis due to</SPAN><SPAN lang=EN-US> functional variation</SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>s</SPAN><SPAN lang=EN-US> of FXR</SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-US> </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB><FONT color=#000000 size=3 face=Calibri>result in cholestatic conditions such as Intrahepatic cholestasis of pregnancy (ICP)</FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>ICP is a pregnancy-specific liver disorder </FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>characterized by pruritus (intense itch) an abnormal liver function </FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-list: l0 level1 lfo1" class=MsoNormal><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><FONT size=3><FONT face=Calibri><SPAN lang=EN-US>The dysfunction of maternal liver could induce stress on the fetal liver as </SPAN><SPAN style="mso-ansi-language: EN-GB" lang=EN-GB>the </SPAN><SPAN lang=EN-US>fetus relies on maternal liver to remove bile. It has been shown that ICP pregnancies are more likely to suffer from meconium staining of the amniotic fluid (MSAF), cardiotocography (GCT) abnormalities and respiration distress syndrome (RDS).</SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-list: l0 level1 lfo1" class=MsoNormal><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>The risk of complications such preterm labor, prenatal death and stillbirth are directly linked to severity of ICP </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-list: l0 level1 lfo1" class=MsoNormal><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>The morbidity of ICP is geographically and racially dependent. [1]</FONT></SPAN></FONT></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <TABLE style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; MARGIN: auto auto auto 18pt; BORDER-COLLAPSE: collapse; BORDER-TOP: medium none; BORDER-RIGHT: medium none; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-yfti-tbllook: 1184; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt" class=MsoTableGrid border=1 cellSpacing=0 cellPadding=0>
| |
| - | <TBODY>
| |
| - | <TR style="mso-yfti-irow: 0; mso-yfti-firstrow: yes">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><B style="mso-bidi-font-weight: normal"><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-fareast-font-family: 宋体; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-font-kerning: 0pt; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>Country<o:p></o:p></FONT></FONT></SPAN></B></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: black 1pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><B><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-themecolor: text1" lang=EN-US>Morbidity(%) </SPAN></B><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt; mso-themecolor: text1" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 1">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>Sweden</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>4.2</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 2">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>Finland</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>1.0</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 3">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>Poland</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>1.5</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 4">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; LINE-HEIGHT: 14.95pt; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan; mso-line-height-rule: exactly; tab-stops: 45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-font-kerning: 0pt" lang=EN-US>Jugoslavia</SPAN><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US> </SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>1.1</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 5">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>Spain</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>1.6</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 6">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>UK</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>1.0</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 7">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>China</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt; mso-pagination: widow-orphan" class=MsoNormal align=center><FONT size=3><FONT face=Calibri><SPAN style="COLOR: black; mso-bidi-font-size: 10.5pt; mso-ascii-font-family: Calibri; mso-fareast-font-family: 宋体; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>4.4</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt; mso-fareast-font-family: 宋体; mso-font-kerning: 0pt" lang=EN-US><o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 8">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" align=center><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>Aymara</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt" lang=EN-US><o:p></o:p></SPAN></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" align=center><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>13.8</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt" lang=EN-US><o:p></o:p></SPAN></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 9">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" align=center><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>Araucanian </SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt" lang=EN-US><o:p></o:p></SPAN></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" align=center><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>27.6</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt" lang=EN-US><o:p></o:p></SPAN></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 10">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" align=center><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>Chile</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt" lang=EN-US><o:p></o:p></SPAN></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" align=center><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>15.6</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt" lang=EN-US><o:p></o:p></SPAN></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | <TR style="mso-yfti-irow: 11; mso-yfti-lastrow: yes">
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: black 1pt solid; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" align=center><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt" lang=EN-US>Caucasian species</SPAN><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt; mso-bidi-font-family: 'Times New Roman'" lang=EN-US> </SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt" lang=EN-US><o:p></o:p></SPAN></P>
| |
| - | </TD>
| |
| - | <TD style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: #f0f0f0; PADDING-BOTTOM: 0cm; BACKGROUND-COLOR: transparent; PADDING-LEFT: 5.4pt; WIDTH: 204.05pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: #f0f0f0; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0cm; mso-border-alt: solid black .5pt; mso-border-themecolor: text1; mso-border-left-alt: solid black .5pt; mso-border-left-themecolor: text1; mso-border-top-alt: solid black .5pt; mso-border-top-themecolor: text1; mso-border-bottom-themecolor: text1; mso-border-right-themecolor: text1" vAlign=top width=272>
| |
| - | <P style="TEXT-ALIGN: center; MARGIN: 0cm 0cm 0pt" align=center><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; COLOR: black; FONT-SIZE: 10.5pt; mso-bidi-font-family: 'Times New Roman'" lang=EN-US>9.8</SPAN><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 18pt" lang=EN-US><o:p></o:p></SPAN></P>
| |
| - | </TD>
| |
| - | </TR>
| |
| - | </TBODY>
| |
| - | </TABLE>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 18pt" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>2.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>Mechanism:-</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 15.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 1.5" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 15.75pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 1.5" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>FXR based activation:-</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-ansi-language: SK" lang=SK><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3><FONT face=Calibri>use eukaryotic transcription factors in bacterial gene expression<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-ansi-language: SK" lang=SK><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3><FONT face=Calibri>suggested use of FXR (known structure and DNA sequence) with constitutive promoter expression<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-ansi-language: SK" lang=SK><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3><FONT face=Calibri>a receptor protein of a number of bile acids, which would bind to ligand-bile acid<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3 face=Calibri>can act as a repressor or an activator, we would use it as an activator, binding to a promoter region B4-BARE (2.4kb) taken from a gene UGT2B4, (known primers for promoter region)</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3 face=Calibri>specified exact FXR binding site, therefore possibility of integrating FXR binding site into another regulatory region</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3 face=Calibri>upon binding to bile acid it would activate output gene</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3 face=Calibri>In the experiment using FXR as transcription factor in human cells 30mM DCA was used, however presumably lower concentration should be sufficient for triggering of FXR.</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>3.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>Output:-</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3 face=Calibri>GFP:-</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3><FONT face=Calibri><FONT color=#000000>fluorescence = light indicator<o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN style="mso-spacerun: yes"> </SPAN>= hard to quantify <o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>ligaments:-</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>colour = clear indicator</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN style="mso-spacerun: yes"> </SPAN>= influenced by the red colour of blood cells</FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN style="mso-spacerun: yes"> </SPAN>= cell free mechanism for hospital use = accurate measurement</FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN style="mso-spacerun: yes"> </SPAN>= filter/ membrane mechanism for home use</FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3 face=Calibri>protein expressed on surface of bacteria causing aggregation</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3><FONT face=Calibri><FONT color=#000000>(either of bacteria or of bacteria to a substance in blood) <o:p></o:p></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-ansi-language: SK" lang=SK><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-ansi-language: SK" lang=SK><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>4.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: SK" lang=SK><FONT size=3><FONT face=Calibri>Modelling:-<o:p></o:p></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>Binding of activator to GFP gene is a positive cooperative reaction.</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-SG><FONT size=3 face=Calibri>Once activator molecule is bound to the enzyme, its affinity for other activator molecules increases. </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><FONT size=3><FONT face=Calibri><SPAN lang=EN-US>Hence, Hill equation can be used as a model.</SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-US> </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-no-proof: yes" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000><?xml:namespace prefix = v ns = "urn:schemas-microsoft-com:vml" /><v:shapetype id=_x0000_t75 stroked="f" filled="f" path="m@4@5l@4@11@9@11@9@5xe" o:preferrelative="t" o:spt="75" coordsize="21600,21600"><v:stroke joinstyle="miter"></v:stroke><v:formulas><v:f eqn="if lineDrawn pixelLineWidth 0"></v:f><v:f eqn="sum @0 1 0"></v:f><v:f eqn="sum 0 0 @1"></v:f><v:f eqn="prod @2 1 2"></v:f><v:f eqn="prod @3 21600 pixelWidth"></v:f><v:f eqn="prod @3 21600 pixelHeight"></v:f><v:f eqn="sum @0 0 1"></v:f><v:f eqn="prod @6 1 2"></v:f><v:f eqn="prod @7 21600 pixelWidth"></v:f><v:f eqn="sum @8 21600 0"></v:f><v:f eqn="prod @7 21600 pixelHeight"></v:f><v:f eqn="sum @10 21600 0"></v:f></v:formulas><v:path o:connecttype="rect" gradientshapeok="t" o:extrusionok="f"></v:path><o:lock aspectratio="t" v:ext="edit"></o:lock></v:shapetype><v:shape style="WIDTH: 184.5pt; HEIGHT: 37.5pt; VISIBILITY: visible; mso-wrap-style: square" id=图片_x0020_1 type="#_x0000_t75" o:spid="_x0000_i1029"><v:imagedata chromakey="white" o:title="" src="file:///C:\Users\ADMINI~1\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png"></v:imagedata></v:shape></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN lang=EN-US>Hill function for transcriptional activation:</SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-US> </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN lang=EN-US>k<SUB>1</SUB>: Maximal transcription rate</SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-US> </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN lang=EN-US>K<SUB>m</SUB>: Activation coefficient</SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-US> </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><FONT size=3><FONT face=Calibri><FONT color=#000000><SPAN lang=EN-US>n: Hill coefficient</SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-US> </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>A: [activator]</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 21pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 2.0" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><FONT size=3><FONT face=Calibri><SPAN lang=EN-US>This equation gives the </SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-SG>% bound by activator as a function of activator concentration. </SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-no-proof: yes" lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000><v:shape style="WIDTH: 225.75pt; HEIGHT: 30.75pt; VISIBILITY: visible; mso-wrap-style: square" id=图片_x0020_2 type="#_x0000_t75" o:spid="_x0000_i1028"><v:imagedata chromakey="white" o:title="" src="file:///C:\Users\ADMINI~1\AppData\Local\Temp\msohtmlclip1\01\clip_image003.png"></v:imagedata></v:shape><v:shape style="WIDTH: 225.75pt; HEIGHT: 32.25pt; VISIBILITY: visible; mso-wrap-style: square" id=图片_x0020_3 type="#_x0000_t75" o:spid="_x0000_i1027"><v:imagedata chromakey="white" o:title="" src="file:///C:\Users\ADMINI~1\AppData\Local\Temp\msohtmlclip1\01\clip_image005.png"></v:imagedata></v:shape></FONT></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><FONT size=3><FONT face=Calibri><SPAN lang=EN-US>after Hill equation modification, the system behaves like a switch</SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-US> </SPAN><SPAN style="mso-no-proof: yes" lang=EN-US><v:shape style="WIDTH: 222.75pt; HEIGHT: 147.75pt; VISIBILITY: visible; mso-wrap-style: square" id=图片_x0020_5 type="#_x0000_t75" o:spid="_x0000_i1026" alt="File:Error Function.svg"><v:imagedata o:title="Error Function" src="file:///C:\Users\ADMINI~1\AppData\Local\Temp\msohtmlclip1\01\clip_image007.png"></v:imagedata></v:shape></SPAN><SPAN style="mso-ansi-language: EN-SG" lang=EN-US><SPAN style="mso-spacerun: yes"> </SPAN></SPAN></FONT></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>In addition, we also need to model the diffusion of blood and GFP in the bacteria culture</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>5.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>Cell –free mechanism:-</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>for hospital use, the blood must be processed through a cell-free system to give an accurate test result, as well as the bacteria to reduce the risk if they leak from the container ( after the cell-free process, the bacteria are not able to reproduce)</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>separate certain organelles from whole cells for further analysis of specific parts of cells</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>in the process, a tissue sample is first homogenised to break the cell membranes and mix up the cell contents</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>homogenization is intensive blending of mutually related substances or groups of mutually related substances to form a constant of different insoluble phases </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>homogenate is then subjected to repeated centrifugations </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>each time removing the pellet and increasing the centrifugal force </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>Separation is based on size and density, with larger and denser particles pelleting at lower centrifugal forces.in the separating order in actual application:</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 31.5pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 3.0" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>Whole cells and nuclei;</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 31.5pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 3.0" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>Mitochondria, lysosomes and peroxisomes;</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 31.5pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 3.0" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>Microsomes (vesicles of disrupted endoplasmic reticulum); ribosomes and cytosol.</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 31.5pt; MARGIN: 0cm 0cm 0pt; mso-char-indent-count: 3.0" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l2 level1 lfo2" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>6.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>Filter/semi-permeable membrane for the blood cells:-</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 39pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>RBC: 7~8.5μm </FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 39pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>neutrophil: 10~12μm </FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 39pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>eosinophil: 10~15μm </FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 39pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>basophil: 10~12μm </FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 39pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>monocyte: 14~20μm </FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 39pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>lymphocyte: small: 6~8μm, medium9~12μm, large: 13~20μm </FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt 17.95pt; mso-para-margin-left: 1.71gd" class=MsoListParagraph><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri>taurocholic acid molecule roughly 0.4nm</FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>therefore, if the hole diameter of the filter is set to be at about 2~5nm, all the blood cells can be filtered </FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="mso-no-proof: yes" lang=EN-US><v:shape style="WIDTH: 179.25pt; HEIGHT: 156.75pt; VISIBILITY: visible; mso-wrap-style: square" id=图片_x0020_6 type="#_x0000_t75" o:spid="_x0000_i1025"><v:imagedata o:title="6312999372498" src="file:///C:\Users\ADMINI~1\AppData\Local\Temp\msohtmlclip1\01\clip_image009.jpg"><FONT color=#000000 size=3 face=Calibri></FONT></v:imagedata></v:shape></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-SIZE: 12pt; mso-bidi-font-size: 11.0pt" lang=EN-US><FONT face=Calibri><FONT color=#000000>AFTERNOON:-<o:p></o:p></FONT></FONT></SPAN></B></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><B style="mso-bidi-font-weight: normal"><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></B></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><B style="mso-bidi-font-weight: normal"><SPAN lang=EN-US><FONT size=3><FONT face=Calibri><FONT color=#000000>LSE BIOS sessions about human practice:-<o:p></o:p></FONT></FONT></FONT></SPAN></B></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l1 level1 lfo3" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>A.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>why biosensors ?</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>possible to construct</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>has a potential market</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><o:p><FONT size=3 face=Calibri> </FONT></o:p></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l1 level1 lfo3" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>B.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>human practice</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>1.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>bio-safety</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -21.25pt; MARGIN: 0cm 0cm 0pt 2cm; mso-char-indent-count: 0; mso-list: l0 level1 lfo1; tab-stops: 49.65pt" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>cell-free system to stop the bacteria from reproducing if there is a leakage of the sensor device</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -21.25pt; MARGIN: 0cm 0cm 0pt 2cm; mso-char-indent-count: 0; mso-list: l0 level1 lfo1; tab-stops: 49.65pt" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>(unpredictable) mutation must be carefully prevented during the engineering part</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>2.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>bio-security</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 17.45pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3><FONT face=Calibri><SPAN style="mso-spacerun: yes"> </SPAN>the access to DNA sequences and other genetic information must be controlled</FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 17.45pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>“garage biologist”</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -7.1pt; MARGIN: 0cm 0cm 0pt 42.55pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3><FONT face=Calibri>the restriction to synthetic biology knowledge is not the way to prevent bio-terrorism, <SPAN style="mso-spacerun: yes"> </SPAN>the key thing is the professional and correct guidance <SPAN style="mso-spacerun: yes"> </SPAN></FONT></FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>3.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>IP (intellectual property issue) and patent</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>4.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>ethical and philosophy</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l3 level1 lfo4" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>5.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>global fairness</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 17.45pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>bio-sensing = faster disease detection</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 17.45pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>employment problem? discrimination?</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 17.45pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>classify the diseases into different levels of risks</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 17.45pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>social coordinate organization to optimize the occupation and personnel resources</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 35.45pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l1 level1 lfo3" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>C.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>LEGO exercise:-</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>different ways to describe the construction process</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><FONT color=#000000><SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN lang=EN-US><FONT size=3 face=Calibri>engineering language and user-friendly language</FONT></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><B style="mso-bidi-font-weight: normal"><SPAN style="COLOR: #7030a0" lang=EN-US><FONT size=3><FONT face=Calibri>new idea<o:p></o:p></FONT></FONT></SPAN></B></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><B style="mso-bidi-font-weight: normal"><SPAN style="COLOR: #7030a0" lang=EN-US><FONT size=3><FONT face=Calibri>inflammation detecting bandage:-<o:p></o:p></FONT></FONT></SPAN></B></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><SPAN style="COLOR: black; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>inflammation is caused by the immune response to pathogens<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><SPAN style="COLOR: black; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>can be acute to chronic<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><o:p><FONT size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><SPAN style="COLOR: black; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><FONT size=3><FONT face=Calibri><B style="mso-bidi-font-weight: normal"><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US>acute</SPAN></B><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US> inflammation:-<o:p></o:p></SPAN></FONT></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l4 level1 lfo5" class=MsoListParagraph><SPAN style="COLOR: black; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>1.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>increased movement of plasma and leukocytes (granulocytes) from blood to injured tissues<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l4 level1 lfo5" class=MsoListParagraph><SPAN style="COLOR: black; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>2.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>causative agent = pathogens and injured tissues<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l4 level1 lfo5" class=MsoListParagraph><SPAN style="COLOR: black; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>3.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>cells involved:<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>neutrophils, mononuclear cells (monocytes and macrophagens)<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0; mso-list: l4 level1 lfo5" class=MsoListParagraph><SPAN style="COLOR: black; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>4.</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>primary mediator = vasoactive amine and eicosanoids<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 0pt 36pt; mso-char-indent-count: 0" class=MsoListParagraph><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><o:p><FONT size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><SPAN style="COLOR: black; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>to carry out the detection mechanism, we will set a target chemical to detect<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><SPAN style="COLOR: black; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>at this stage, <I style="mso-bidi-font-style: normal">interferon gamma </I>is taken into our consideration<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P><FONT color=#000000><I style="mso-bidi-font-style: normal"><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 10.5pt; mso-bidi-font-size: 12.0pt; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-bidi-font-weight: bold; mso-ansi-language: EN" lang=EN>Interferon-gamma</SPAN></I><I style="mso-bidi-font-style: normal"><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 10.5pt; mso-bidi-font-size: 12.0pt; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN" lang=EN> (<SPAN style="mso-bidi-font-weight: bold">IFN-γ</SPAN>) is a dimerized soluble cytokine that is the only member of the type II class of interferon.<o:p></o:p></SPAN></I></FONT></P>
| |
| - | <P><FONT color=#000000><I style="mso-bidi-font-style: normal"><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 10.5pt; mso-bidi-font-size: 12.0pt; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN" lang=EN>This interferon was originally called <B style="mso-bidi-font-weight: normal">macrophage-activating factor</B>, a term now used to describe a larger family of proteins to which IFN-γ belongs. In humans, the IFN-γ protein is encoded by the <SPAN style="mso-bidi-font-style: italic">IFNG</SPAN> gene.</SPAN></I><SPAN style="FONT-FAMILY: 'Calibri','sans-serif'; FONT-SIZE: 10.5pt; mso-bidi-font-size: 12.0pt; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN" lang=EN>[2]<o:p></o:p></SPAN></FONT></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><SPAN style="COLOR: black; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>the goal of this project is to find a gene coding the protein which and react with interferon gamma and give an indication<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="TEXT-INDENT: -18pt; MARGIN: 0cm 0cm 0pt 18pt; mso-char-indent-count: 0; mso-list: l0 level1 lfo1" class=MsoListParagraph><SPAN style="COLOR: black; mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: Calibri; mso-themecolor: text1" lang=EN-US><SPAN style="mso-list: Ignore"><FONT size=3 face=Calibri>-</FONT><SPAN style="FONT: 7pt 'Times New Roman'"> </SPAN></SPAN></SPAN><SPAN style="COLOR: black; mso-themecolor: text1" lang=EN-US><FONT size=3><FONT face=Calibri>a further step may be taken as a “damaged tissue cleaner”, which means that the bacteria can not only detect but also remove the inflammation tissue<o:p></o:p></FONT></FONT></SPAN></P>
| |
| - | <P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN lang=EN-US><o:p><FONT color=#000000 size=3 face=Calibri> </FONT></o:p></SPAN></P>
| |
| - | <DIV style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000><FONT size=3><FONT face=Calibri><SPAN style="mso-spacerun: yes"> </SPAN>[1] </FONT></FONT></FONT><A href="http://baike.baidu.com/view/676699.htm"><FONT color=#800080 size=3 face=Calibri><A href="http://baike.baidu.com/view/676699.htm">http://baike.baidu.com/view/676699.htm</FONT></A></SPAN><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri></FONT></SPAN></A></DIV>
| |
| - | <DIV style="MARGIN: 0cm 0cm 0pt" class=MsoNormal><SPAN lang=EN-US><FONT color=#000000 size=3 face=Calibri><FONT color=#444444 size=2 face=Arial> </FONT>[2] http://en.wikipedia.org/wiki/Interferon-gamma</FONT></SPAN></DIV>
| |
| - | </html>
| |
| - | <html>
| |
| - | <b><br><br>Christopher Schoene<br><br></b>
| |
| - | More Ig research: <br><br>
| |
| - | To generate cell surface anchored antibody fragments: VHH sequence is fused to the anchor sequence from proteinase P of L. casei. <br><br>
| |
| - | To generate the secreted VHH, stop codon after E-tag. <br><br>
| |
| - | <b>Sand brick research:</b><br><br>
| |
| - | Sporosarcina pasteurii --> urease<br><br>
| |
| - | Calcium carbonate bricks can be made by using urease, urea, sand and calcium chloride. The urease cleaves the urea and creates ammonia and carbon dioxide. The ammonia raises the pH and causes the calcium ions to precipitate with the dissolved carbonate ions. <br><br>
| |
| - | Ammonia is currently a problem since it can run off to cause algal bloom. A method to remove ammonia must be obtained. Solution? Possibly express all the urea cycle enzymes in the chassis (5 total enzymes). Use slovenia's DNA scaffold so that the process does not produce too many possibly problematic intermediaries in the bacteria. <br><br>
| |
| - | When should ammonia be converted back to urea? When calcium is depleted. Need some sort of Calcium sensor. <br><br>
| |
| - | <b>New way of transforming bacteria idea:</b><br><br>
| |
| - | New way of selecting for transformed bacteria. <br><br>
| |
| - | Create a plasmid containing Dpn1 under the influence of a strong repressor. In the same plasmid insert the methylase enzyme. The gene is inserted into the methylase and stops its transcription. <br><br>
| |
| - | If the gene of interest has been successfully inserted into the plasmid and the plasmid has been successfully inserted into the bacteria we can use the inducer to kill off any bacteria that has not been transformed (because the Dpn1 cuts any methylated strands of DNA). <br><br>
| |
| - | Today we continued developing the bile acid sensor as well as the idea of the anti-venom. For the anti-venom idea we talked to Travis Bayer and obtained a method for screening for the right mutants. We also had a visit from LSE BIOS members that taught us about the point points we should worry about in human practices. We were also given the task to make instructions for a lego structure to show us how difficult it is to standardize parts due to the difficulty of communicating more complicated instructions.
| |
| - | </html>
| |
| - | <br>
| |
| - | <br>
| |
| - | <html>
| |
| - | <br>
| |
| - | <br>
| |
| - | <b>Frank Machin</b><br>
| |
| - | <br>
| |
| - | http://www.msnbc.msn.com/id/32558231/ns/technology_and_science-science/t/study-bacteria-can-make-salt-water-drinkable/
| |
| - | <br> So that's pretty cool, but perhaps the bacteria that store salt can be used to spread salt in the winter and stop the country grinding to a halt every time it snows?
| |
| - | </html>
| |
| - | <br>
| |
| - | <br>
| |
| - | <br>
| |
| - | '''Bacterial Spores & Rain'''
| |
| - | <br>
| |
| - | The surface of spores can form crystal structures that attract water vapour from the air and form rain drops. We wanted to use this priniciple to have a useful output from the spores when they reach the ground - which could be sand or soil.<br>
| |
| - | <br>
| |
| - | There are several genes localized that contribute to the spore outer layer which could potentially be randomly mutated to optimize the geometric shape of the spore to promote water droplet formation.<br>
| |
| - | <br>
| |
| - | One of the drawbacks to using spores is that we need germination to occur for gene expression and there is an obvious risk of releasing GMOs into nature. One option could be to engineer in a death response to have limited gene expression of mucin for example which could aid in water retention, or auxin to promote root growth deep into soil.
| |
| - |
| |
| - | <html>
| |
| - | <br><br><b>Greenhouse Gases (isoprene)</b><br><br>
| |
| - | 1.Water vapor<br>
| |
| - | 2. Carbon dioxide - done to death<br>
| |
| - | 3. Methane<br>
| |
| - | 4. Ozone<br><br>
| |
| - | CFC's, VOC's and Nitrous oxide. CFC's are banned. However, chlorine radicals still a problem. <br>
| |
| - | isoprene is produced by plants to prevent oxidative stress and heat shock. VOC. Byproduct of the thermal cracking of naphtha or oil. Used to produce natural rubber... <br>
| |
| - | Produced from the precursor DMAPP<br>
| |
| - | DMAPP is made by isopentenyl pyrophosphate isomerase from IPP. <br>
| |
| - | IPP is also one of the precursors of of lycopene. You need 3 IPP, 1 DMAPP and 1 GGPP (Geranylgeranyl pyrophosphate) to produce Phytoene. <br>
| |
| - | Insert lycopene biosynthesis pathway and inhibit isoprene synthase? <br>
| |
| - | Probably too complicated. <br></html>
| |
| - | [[File:Isoprene_degradation.png]] <br>
| |
| - | <html>
| |
| - | 1. Johan E. T. van Hylckama Vlieg et al., “Characterization of the Gene Cluster Involved in Isoprene Metabolism in Rhodococcus sp. Strain AD45,” Journal of Bacteriology 182, no. 7 (April 2000): 1956-1963. <br><br>
| |
| - |
| |
| - | Rhodococcus sp. strain AD45<br>
| |
| - | Isoprene is supposed to recycle OH. NOx causes oxidant build-up. <br>
| |
| - | Mechanism for NOx removal? <br>
| |
| - | NO sources: Internal combustion engine. Cannot target. <br>
| |
| - | NO2 sources: Internal combustion engine, thermal power station, pulp mill. None of which could be targeted. <br>
| |
| - | Pulp mill industry is one of the largest producers of water pollution in the world. An alternative to paper could solve a lot of problems. Still unfeasible. <br>
| |
| - | Containment is an issue.
| |
| - | </html>
| |
| - | <html>
| |
| - | <br><br><b>DNA assembly presentation:</b><br><br>
| |
| - | DNA assembly can kill rpojects if done incorrectly. It takes around 3 days for 1 assembly: <br>
| |
| - | Day 1: Start cultures<br>
| |
| - | Day 2: Assemble<br>
| |
| - | Day 3: Screen (might take more than one day). <br><br>
| |
| - | Assembly day: <br>
| |
| - | Miniprep ~30 mins.<br>
| |
| - | Extract part ~75-135 mins.<br>
| |
| - | Purify part ~90 mins. <br>
| |
| - | Assemble (make flanking sequences single stranded and mix and anneal) ~75-135 mins. <br>
| |
| - | Transform ~60 mins. <br>
| |
| - | <b>~6.5 hours! That is being optimistic!</b><br><br>
| |
| - | Two techniques: <br>
| |
| - | Short Overlap (biobricks)- Maximum two parts at the same time. <br>
| |
| - | Long overlap (Gibson/User) - Safely assemble 5 parts, theoretically 10. <br><br>
| |
| - | Short: <br>
| |
| - | Miniprep --> Restriction digest --> Gel extract --> Ligate--> Transform<br>
| |
| - | All parts submitted must be in this format. Can use the parts from miniprep a maximum of around 4 times. <br>
| |
| - | ~6 bp overhang. Low Tm (~10 degrees celsius). Ligase works best at 37 degrees celsius though. Need to compromise between both these paramters. <br><br>
| |
| - | Long: <br>
| |
| - | Miniprep --> PCR --> DpnI digest + purify or gel extract --> Assembly reaction--> Transform<br>
| |
| - | PCR primer could work first time or take weeks to get to work due to possibilities of non-specific binding and other errors that can occur with an inadequate primer. <br>
| |
| - | Gibson ~40bp overhang while User ~20bp overhang. User require a uracil for every 7th base. Uracils are expensive bases to buy. <br>
| |
| - | Gibson still work for DNA fragments down to ~91bp. Need to be careful that they're not too much shorter. <br><br>
| |
| - | Part insulation: <br>
| |
| - | If 2 ORF's are next to each other one might transcribe into another. Solve through three methods: <br>
| |
| - | 1: Place a terminator in between. Problem is that if there are too many terminators with the same sequence, deletions might occur. Check Biofab IS website for different terminators.<br>
| |
| - | 2: Face parts away from each other. <br>
| |
| - | 3: Spacing them away from each other. However, read-through is very long. <br><br>
| |
| - | Reusable parts: <br>
| |
| - | Biobricks allows us to reuse parts easily. Can this be done with the Long overhang methods? <br>
| |
| - | Prefix and suffix attached to GOI. Use linkers. Depending on linker we attach one GOI to another in whatever orientation and order we want. <br><br>
| |
| - | Libraries: <br>
| |
| - | Three types: Mutants, Mutagenomics and Rational design. <br>
| |
| - | Sources: Other labs/registries, epPCR, degenerate synthesis.
| |
| - | </html>
| |
"
